Shehata AH, Anter AF, Ahmed ASF
In line with FDA guidance that clinicians monitor for new or worsening depression, suicidal thoughts, or unusual changes in mood during GLP-1 RA treatment [46], brief psychological screening should be incorporated at baseline and repeated at intervals during treatment at weeks 6, 12, and 24, and then at least every six months
This finding suggests that the tanning peptide may play a role in enhancing repigmentation strategies
Septic-associated encephalopathy: A comprehensive review
Notably, statistics reveal that approximately 40% of patients taking semaglutide reported no heavy drinking days, compared to just 20% in the placebo group, highlighting the potential benefits of this therapy in relation to alcohol and GLP-1